Sandeep Kalra, MD
Internal Medicine · Naperville, ILNPI 1376622092
Payments from drug & device makers
Across 86 payments — averaging $16.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$283
- AbbVie$133
- Amgen$124
- AstraZeneca$92
- Corcept Therapeutics$85
- Abbott$83
- plus $588 from 23 others
What the payments were for
- Food & beverage$1,389100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 23 | $283 |
| AbbVie | 7 | $133 |
| Amgen | 7 | $124 |
| AstraZeneca | 5 | $92 |
| Corcept Therapeutics | 5 | $85 |
| Abbott | 4 | $83 |
| Novo Nordisk | 5 | $79 |
| Novartis | 4 | $53 |
| Ascensia Diabetes Care US Inc. | 2 | $41 |
| Lilly USA, LLC | 3 | $38 |
| Masimo Corporation | 1 | $35 |
| Amarin Pharma, Inc. | 2 | $32 |
| Boston Scientific | 1 | $27 |
| Kyowa Kirin, Inc. | 1 | $24 |
| BETA Bionics, Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Shionogi Inc | 1 | $20 |
| Merck | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Adlon Therapeutics L.p. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $15 |
| GSK | 1 | $14 |
| Pfizer | 1 | $14 |
| Medtronic | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$1,389 in reported general payments places this provider in the 80th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,124 | $301,872 |
| XtandiEnzalutamide | 12 | $176,831 |
| XifaxanRifaximin | 79 | $110,445 |
| NuplazidPimavanserin Tartrate | 42 | $104,606 |
| XareltoRivaroxaban | 421 | $103,759 |
| JanuviaSitagliptin Phosphate | 262 | $61,676 |
| MyrbetriqMirabegron | 250 | $46,227 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 86 | $42,973 |
| JardianceEmpagliflozin | 109 | $40,051 |
| Memantine Hcl | 964 | $30,405 |
| Atorvastatin Calcium | 2,095 | $30,092 |
| FarxigaDapagliflozin Propanediol | 120 | $29,756 |
| TrulicityDulaglutide | 21 | $22,042 |
| OzempicSemaglutide | 21 | $21,418 |
| Levothyroxine Sodium | 1,758 | $19,990 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Retacrit | $14 | $314,6691,180 claims |
| Johnson & JohnsonXarelto, Procrit | $283 | $120,869457 claims |
| MerckJanuvia, Lagevrio (Eua) | $19 | $78,048278 claims |
| GSKTrelegy Ellipta, Arexvy, Breo Ellipta | $14 | $75,777179 claims |
| AstraZenecaFarxiga, Lokelma | $92 | $49,388170 claims |
| AbbVieCreon, Linzess | $133 | $29,55140 claims |
| Lilly USA, LLCTrulicity | $38 | $22,04221 claims |
| Novo NordiskOzempic | $79 | $21,41821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Naperville
- Shivani KirilukNaperville$1.1M
- Iffat AhmedNaperville$186K
- Carol WeinbergNaperville$110K
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.